Rolling Out Depot Buprenorphine – there is no Red Carpet

It will soon be 2 years since the first depot buprenorphine product (Buvidal®) was made available in Australia via a product familiarisation programme, 18 months since it was TGA approved, and a year since another depot buprenorphine product (Sublocade®) was PBS listed, for treatment of opioid dependence. In this seminar we look at challenges in the delivery of this treatment modality in a range of metropolitan and regional settings as a case study for the larger question of how to make addiction treatment more available to the people who need it, whoever and wherever they are.